A 2026 randomized trial of 74 psychiatric inpatients found that 5 consecutive MIDI-assisted group music therapy sessions reduced DASS-21 stress more than 1 session during the same hospital week, but the frequency advantage did not extend to anxiety, depression, life satisfaction, or immediate session-impact ratings. Research Highlights Stress separated by frequency: 5 sessions produced a …
A 2026 participatory-design and case-study paper turned smartphone mental-health data into 6 clinician-facing visualizations for an 8-week anxiety/depression digital clinic, using feedback from 15 clinicians and 3 clinical supervisors. The useful claim is workflow-level: charts made passive sensing and symptom ratings discussable inside care, but the paper did not test whether the visualizations improved clinical …
The broad cytokine story failed its most direct community test: in 972 adults, depression, alcohol use, and alcohol use disorder (AUD) were not associated with C-reactive protein (CRP) or a pre-registered pro-inflammatory cytokine index. The only multiple-testing-corrected cytokine hits ran opposite the hypothesis — AUD was linked to lower IL-1β, IL-4, IL-10, and IL-12 — …
A 12-week randomized pilot trial in 60 Veterans with depression and psychiatric polypharmacy found that 30% had an actionable antidepressant gene-drug interaction, but immediate access to pharmacogenomic results did not clearly change prescribing or Patient Health Questionnaire-9 depression scores compared with delayed access.1 Research Highlights Actionable PGx results were common: 18 of 60 Veterans, or …
A 2026 nationwide Korean analysis found that resistance exercise was associated with lower depression and anxiety scores after propensity score matching, while aerobic exercise alone was not significantly associated with either outcome. The result favors adding weights, bands, machines, or body-weight strength work to mental-health exercise advice without assuming that lifting caused the lower symptom …
A 2026 multimodal MRI study found that treatment-resistant depression had lower coordination between brain structure and brain activity than non-treatment-resistant depression in frontal, parietal, motor, and temporal regions. Machine-learning models using those structure-function coupling measures classified treatment-resistant vs. non-treatment-resistant depression with AUC values from 0.886 to 0.950 in the primary atlas analysis.1 Research Highlights TRD …
Intranasal esketamine — FDA-approved for treatment-resistant depression in 2019 — failed cost-effectiveness benchmarks against four cheaper third-line options in a 2026 Hong Kong modeling study, with incremental cost-effectiveness ratios (ICERs) of US$134,127 to US$312,750 per quality-adjusted life-year (QALY) at a US$50,000/QALY willingness-to-pay (WTP) threshold.1 Combination antidepressant therapy was the most cost-effective strategy modeled. Research Highlights …